Who we are
The Nucleic Acid Therapy Accelerator (NATA) is a not-for-profit Medical Research Council (MRC) Unit uniquely positioned within UK Research and Innovation (UKRI). We operate at the intersection of academia, preclinical research and industry to advance the development of nucleic acid therapies (NATs) and associated technologies through high-quality science, collaborations and interdisciplinary research.
What we do
With a strong focus on real-world impact for patients, we tackle a wide range of disease areas from common disorders to rare diseases as well as evaluating new technologies to improve the delivery and safety of nucleic acid therapies. We work collaboratively with our partners to co-develop value and intellectual property rights, advancing therapeutic targets from validation and lead identification to pre-clinical data generation. We aim to develop novel therapeutics, from broadly applicable disease modifying pathways to personalised medicines tailored to individual patients.
How we are funded
NATA is funded by £30M of public investment from the UK Strategic Priorities Fund through the Medical Research Council (MRC) and UK Research and Innovation (UKRI), as part of the UK Government’s National Productivity Investment Fund.
